WO2012169741A3 - ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 - Google Patents

ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 Download PDF

Info

Publication number
WO2012169741A3
WO2012169741A3 PCT/KR2012/004247 KR2012004247W WO2012169741A3 WO 2012169741 A3 WO2012169741 A3 WO 2012169741A3 KR 2012004247 W KR2012004247 W KR 2012004247W WO 2012169741 A3 WO2012169741 A3 WO 2012169741A3
Authority
WO
WIPO (PCT)
Prior art keywords
fcεri
human antibody
treating
allergic diseases
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/004247
Other languages
English (en)
French (fr)
Other versions
WO2012169741A2 (ko
Inventor
박병덕
윤선주
배종환
박은혜
김욱동
김민희
강현정
유경숙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neopharm Co Ltd
Original Assignee
Neopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Co Ltd filed Critical Neopharm Co Ltd
Priority claimed from KR1020120057081A external-priority patent/KR20120135868A/ko
Publication of WO2012169741A2 publication Critical patent/WO2012169741A2/ko
Publication of WO2012169741A3 publication Critical patent/WO2012169741A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 IgE의 Fc에 고친화성을 갖는 수용체인 FcεRI 특이적 인간 항체 및 이를 수득하는 방법에 대한 것으로, 본 발명에 따른 FcεRI 특이적 항체는 IgE와 FcεRI 사이의 결합을 효율적으로 저해하여, IgE에 의해 매개되는 알레르기성 비염, 천식, 아토피 피부 질환, 두드러기 및 접촉성 피부염 등의 알레르기 질환에 대한 치료 또는 진단 용도로 활용이 가능하다.
PCT/KR2012/004247 2011-06-07 2012-05-30 ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 Ceased WO2012169741A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0054650 2011-06-07
KR20110054650 2011-06-07
KR1020120057081A KR20120135868A (ko) 2011-06-07 2012-05-30 ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
KR10-2012-0057081 2012-05-30

Publications (2)

Publication Number Publication Date
WO2012169741A2 WO2012169741A2 (ko) 2012-12-13
WO2012169741A3 true WO2012169741A3 (ko) 2013-03-07

Family

ID=47296560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004247 Ceased WO2012169741A2 (ko) 2011-06-07 2012-05-30 ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물

Country Status (1)

Country Link
WO (1) WO2012169741A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954307B2 (en) 2016-12-22 2021-03-23 Lipidair, Llc Targeted delivery methods and compositions for antihistamines
EP3840841A1 (en) 2018-08-23 2021-06-30 Regeneron Pharmaceuticals, Inc. Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11174A (ja) * 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Ｆａｂ断片の製造法
WO2002102320A2 (en) * 2001-06-15 2002-12-27 Tanox, Inc. Fce fusion proteins for treatment of allergy and asthma
US20070135621A1 (en) * 2003-04-03 2007-06-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Therapeutic products with enhance ability to immunomodulate cell functions
KR100932465B1 (ko) * 2001-07-19 2009-12-17 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 ＩｇＥ 수용체 항체 및 항체 단편
WO2012037196A1 (en) * 2010-09-14 2012-03-22 The Henry M. Jackson Foundation Methods of treating autoimmune diseases with anti-fceri antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11174A (ja) * 1997-06-13 1999-01-06 Asahi Breweries Ltd 酵母を用いた抗体Ｆａｂ断片の製造法
WO2002102320A2 (en) * 2001-06-15 2002-12-27 Tanox, Inc. Fce fusion proteins for treatment of allergy and asthma
KR100932465B1 (ko) * 2001-07-19 2009-12-17 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 ＩｇＥ 수용체 항체 및 항체 단편
US20070135621A1 (en) * 2003-04-03 2007-06-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Therapeutic products with enhance ability to immunomodulate cell functions
WO2012037196A1 (en) * 2010-09-14 2012-03-22 The Henry M. Jackson Foundation Methods of treating autoimmune diseases with anti-fceri antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHUHEI HASHIGUCHI ET AL.: "Human FceRla-specific human single-chain Fv (scFv) antibody with antagonistic activity toward IgE/FceRIa-binding", THE JOURNAL OF BIOCHEMISTRY, vol. 133, no. 1, 2003, pages 43 - 49 *

Also Published As

Publication number Publication date
WO2012169741A2 (ko) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012106407A3 (en) Diagnostic and therapeutic methods and products related to anxiety disorders
WO2013132260A9 (en) Cross-linked graphene networks
WO2011112687A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2012098345A3 (en) Cross-linked carbon nanotube networks
WO2009063215A3 (en) Use of crth2 antagonist compounds
WO2012045089A3 (en) Methods for the treatment of allergic diseases
EA201390559A1 (ru) Подавление иммунного ответа по типу гиперчувствительности неродственным антигеном, получаемым из материала-источника аллергенов
CR20150101A (es) Anticuerpos que se unen a il-4 y/o il-13
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
MX2009010765A (es) Anticuerpos anti-ige.
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
WO2011112766A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
MX375872B (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas.
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
EP2710370A4 (en) METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2011112731A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2013090633A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
WO2011133661A3 (en) Methods and compositions related to dopaminergic neuronal cells
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2012169741A3 (ko) ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12796779

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12796779

Country of ref document: EP

Kind code of ref document: A2